1. Home
  2. SURG vs MAIA Comparison

SURG vs MAIA Comparison

Compare SURG & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SurgePays Inc.

SURG

SurgePays Inc.

HOLD

Current Price

$1.76

Market Cap

47.6M

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.20

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SURG
MAIA
Founded
2006
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.6M
44.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
SURG
MAIA
Price
$1.76
$1.20
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$9.50
N/A
AVG Volume (30 Days)
133.3K
454.0K
Earning Date
11-12-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,372,555.00
N/A
Revenue This Year
$7.13
N/A
Revenue Next Year
$122.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.05
$0.87
52 Week High
$3.47
$2.74

Technical Indicators

Market Signals
Indicator
SURG
MAIA
Relative Strength Index (RSI) 32.06 53.94
Support Level $1.66 $1.07
Resistance Level $2.01 $1.25
Average True Range (ATR) 0.11 0.12
MACD -0.01 0.04
Stochastic Oscillator 25.32 55.93

Price Performance

Historical Comparison
SURG
MAIA

About SURG SurgePays Inc.

Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: